72 results on '"Bedard P"'
Search Results
2. 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
3. Safety of minimizing intensity of follow-up on active surveillance for clinical stage I testicular germ cell tumors
4. 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
5. 1671MO Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
6. 989P Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)
7. 474P Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE
8. 114P Changes in serum choline (Ch) levels to predict treatment outcomes in advanced cancer patients (pts) treated with immunotherapy (IO)
9. 521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
10. 1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes
11. 38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
12. Role of lactate dehydrogenase (LDH) in identifying relapse for patients with stage I testis cancer on active surveillance
13. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
14. 19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)
15. Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer phase I IO cohort
16. Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
17. Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events
18. Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
19. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
20. Novel patterns of response under immunotherapy
21. Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
22. Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
23. Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment in alcoholic hepatitis subjects
24. CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors
25. Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein
26. First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)
27. Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma
28. Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)
29. Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study
30. Retrospective review of new phase I clinic referrals and enrolment in the molecular screening era
31. Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels
32. Author Financial Conflicts of Interest (Fcois) in Clinical Practice Guidelines (Cpgs) for Systemic Anti-Cancer Drugs
33. Fine Needle Biopsies are Feasible As a Minimally Invasive Means for Targeted Next Generation Sequencing in Advanced Solid Tumors
34. Contemporary Management of Stage I and Stage II Seminoma
35. Evolution of Clinical Trial Design in Early Drug Development: The Use of Expansion Cohorts (ECS) in Phase I Cancer Trials (PITS)
36. A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors
37. A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503)
38. 18 The Neo BIG programme
39. 137 Optimising anti-HER2 therapy in early breast cancer
40. Evaluating Evidence of Activation in fMRI via a Novel Likelihood Paradigm
41. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys
42. Naltrexone in the short-term decreases antiparkinsonian response to -Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys
43. A-86929: A selective dopamine D1 receptor agonist with anti-Parkinsonian efficacy in MPTP-lesioned primate models
44. Chronic idiopathic urticaria: Possible contribution of histamine-releasing factor to pathogenesis
45. Chronic idiopathic urticaria: Profiles of skin mast cell histamine release during active disease and remission
46. Allergic rhinitis to ragweed pollenII. Modulation of histamine-releasing factor production by specific immunotherapy
47. Allergic rhinitis to ragweed pollenI. Reassessment of the effects of immunotherapy on cellular and humoral responses
48. Surface area, XRD, and FTIR spectral characterization of chemically derived PbTiO3 ceramics
49. Commissural fusion in an Ionescu-Shiley bioprosthesis: An unusual cause of valvular stenosis
50. 336 Idiopathic chronic urticaria (CU): Comparison of histamine-releasing factor (HRF) recovered from skin and blood mononuclear cells (MNC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.